PNC-27
A p53-derived research peptide that selectively ruptures the membranes of cancer cells by targeting surface-expressed HDM-2, while sparing normal cells.
PNC-27 is a synthetic p53-derived peptide that combines the p53 transactivation domain (residues 17-26) with a membrane-penetrating HDM-2-binding sequence. It kills cancer cells through direct membranolysis by binding HDM-2 that is aberrantly expressed on the tumor cell surface, a target normal cells lack. Evidence is entirely preclinical (cell culture and rodent xenografts), with no completed human clinical trials, and it is sold strictly as a research-use-only compound.
Class
Synthetic 32-amino-acid p53-derived membranolytic peptide
Half-life
Unknown (no published pharmacokinetic data)
Routes
Subcutaneous, Intravenous, Intraperitoneal
Category
Immune & Mitochondrial
Researched benefits
What it's studied for
Selective cancer cell membranolysis
PNC-27 binds HDM-2 aberrantly expressed on the cancer cell plasma membrane and creates pores that rupture the membrane. Because normal cells retain HDM-2 intracellularly and do not display it on their surface, they are spared, giving the peptide unusual tumor selectivity in vitro.
Activity across multiple cancer types
In cell-culture studies it has shown selective killing of pancreatic cancer, leukemia, breast cancer, and melanoma cells, indicating the mechanism is not restricted to a single tumor lineage. Evidence is in vitro only.
Non-apoptotic killing mechanism
Rather than inducing DNA damage or cell-cycle arrest, PNC-27 causes direct physical membrane destruction, making it a research model for non-apoptotic cancer cell death that could bypass some apoptosis-resistance pathways.
Rapid cytotoxic action
In vitro, membranolysis occurs within minutes of contact with susceptible tumor cells, reflecting a direct membrane-disruption mechanism rather than a slower transcriptional or signaling cascade.
Tumor-selective surface target
Membrane-localized HDM-2 is a tumor-selective surface marker, which is what allows PNC-27 to distinguish malignant from normal cells and is the basis of its mechanistic interest among research-stage anticancer peptides.
Mechanism
How it works
PNC-27 is a chimeric 32-amino-acid peptide built from two functional parts: the p53 transactivation domain (amino acids 17-26), which is the region of p53 that binds HDM-2 (the mouse double minute 2 homolog and negative regulator of p53), and a membrane-penetrating / transmembrane residency sequence that anchors the peptide into lipid membranes.
The tumor selectivity of PNC-27 rests on a specific biological quirk: cancer cells aberrantly express HDM-2 protein on their outer plasma membrane surface, whereas normal cells keep HDM-2 confined intracellularly. PNC-27 binds this surface-exposed HDM-2 on cancer cells, and once localized to the membrane its transmembrane segment inserts into and disrupts the lipid bilayer.
Membrane insertion creates transmembrane pores that compromise membrane integrity, leading to rapid membranolysis (physical destruction of the cell membrane) and cell death. This is a direct, non-apoptotic killing mechanism distinct from DNA-damage or cell-cycle-arrest cytotoxics. Normal cells, lacking surface HDM-2, are not bound and are therefore spared.
All of this mechanism is documented in preclinical systems only, primarily cell culture and rodent xenograft models, with published work coming largely from Sarafraz-Yazdi and colleagues. There is no published human clinical trial data establishing efficacy, pharmacokinetics, or safety in people.
Evidence
Research & clinical studies (1)
Selective membranolysis of cancer cells by PNC-27 targeting membrane-expressed HDM-2 (Sarafraz-Yazdi et al.)
PNC-27 selectively killed pancreatic cancer, leukemia, and breast cancer cells in culture by inducing membranolysis via surface-expressed HDM-2, while sparing normal cells.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Active cancer patients should pursue licensed oncology care rather than this unproven compound
- Not for human consumption or self-treatment
Human safety data for PNC-27 is entirely absent. Preclinical rodent studies have not surfaced major toxicity signals at researched doses, but off-target effects at therapeutic concentrations in vivo are unknown, and long-term human safety is completely uncharacterized. Tumor selectivity depends on membrane HDM-2 expression patterns that may vary.
FAQ
PNC-27 — common questions
Is PNC-27 a cancer treatment?
No. PNC-27 is a preclinical research compound with no published human clinical trials demonstrating cancer efficacy or safety. Despite marketing in some communities, no human evidence exists, and anyone with active cancer should pursue evidence-based oncology care.
How does PNC-27 work?
It combines the p53 transactivation domain with a membrane-penetrating sequence and binds HDM-2 that cancer cells display on their surface. Once anchored, it disrupts the tumor cell membrane and causes rapid membranolysis, while sparing normal cells that do not express surface HDM-2.
Is PNC-27 legal to purchase?
PNC-27 is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption anywhere in the world.
Will PNC-27 be FDA-approved?
No active FDA clinical development program for PNC-27 exists. Approval is unlikely without a registered Phase 1 trial program, which has not been initiated.
What cancers has PNC-27 been tested against?
In cell culture, PNC-27 has shown selective killing of pancreatic cancer, leukemia, breast cancer, and melanoma cells. All of this evidence is in vitro or in rodent xenografts, not from human trials.
Is there a recommended dose?
No. PNC-27 has no published human clinical data, no pharmacokinetic data, and no established therapeutic dose. It is a research-use-only material with no validated human protocol.
What is the most honest framing of PNC-27?
It is a mechanistically interesting preclinical compound with selective tumor-cell-killing activity in cell culture and rodent xenografts, but no human clinical trials. It should not be considered a cancer therapy at the human level.
